Neumora Therapeutics (NMRA) Interest Expenses (2025 - 2026)

Neumora Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Interest Expenses changed N/A year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $3.9 million (changed N/A YoY), while the FY2025 annual figure was $330.2 million, up 24.89% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.9 million, down from $2.0 million in the prior quarter.
• The five-year high for Interest Expenses was $197.3 million in Q4 2023, with the low at $1.0 million in Q3 2025.
• The 5-year median for Interest Expenses is $58.3 million (2024), against an average of $66.6 million.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 39.36% in 2023, then plunged 98.63% in 2025.
• Neumora Therapeutics' Interest Expenses stood at $141.6 million in 2022, then jumped by 39.36% to $197.3 million in 2023, then slumped by 63.02% to $73.0 million in 2024, then tumbled by 97.21% to $2.0 million in 2025, then fell by 8.94% to $1.9 million in 2026.
• Business Quant data shows NMRA's Interest Expenses at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.0 million in Q3 2025.